Baz Mariana, Samant Mukesh, Zekki Hakima, Tribout-Jover Pascale, Plante Martin, Lanteigne Anne-Marie, Hamelin Marie-Eve, Mallett Corey, Papadopoulou Barbara, Boivin Guy
Research Center in Infectious Diseases of the CHUL, CHUQ and Department of Microbiology and Immunology of Laval University, Quebec, Canada.
Clin Vaccine Immunol. 2012 Feb;19(2):209-18. doi: 10.1128/CVI.05441-11. Epub 2011 Dec 21.
Influenza A/H3N2 viruses have caused the most severe epidemics since 1968 despite current immunization programs with inactivated vaccines. We undertook a side-by-side preclinical evaluation of different adjuvants (Alum, AS03, and Protollin) and routes of administration (intramuscular [i.m.] and intranasal [i.n.]) for assessing their effect on the immunogenicity and cross-reactivity of inactivated split vaccines (A/H3N2/New York/55/2004). Humoral and T cell-mediated immune responses against the homologous virus and a heterologous drifted strain (A/H3N2/Wisconsin/67/2005) were measured in BALB/c mice at 2, 6, and 19 weeks postboost. The AS03- and Alum-adjuvanted i.m. vaccines induced at least an 8-fold increase over the nonadjuvanted vaccine in functional antibody titers against both the homotypic and heterotypic strains and low IgG2a and high IgG1 levels, suggesting a mixed Th1/Th2 response with a Th2 trend. The Protollin-adjuvanted i.n. vaccine induced the lowest IgG1/IgG2a ratio, which is indicative of a mixed Th1/Th2-type profile with a Th1 trend. This adjuvanted vaccine was the only vaccine to stimulate a mucosal IgA response. Whatever the timing after the boost, both hemagglutination inhibition (HAI) and microneutralization (MN) titers were higher with the AS03-adjuvanted i.m. vaccine than with the protollin-adjuvanted i.n. vaccine. Finally, the Alum-adjuvanted i.m. vaccine and the lower-dose Protollin-adjuvanted i.n. vaccine elicited significantly higher CD4(+) Th1 and Th2 responses and more gamma interferon (IFN-γ)-producing CD8(+) T cells than the nonadjuvanted vaccine. Our data indicate that the adjuvanted vaccines tested in this study can elicit stronger, more persistent, and broader immune responses against A/H3N2 strains than nonadjuvanted inactivated influenza vaccines.
尽管目前有使用灭活疫苗的免疫计划,但甲型H3N2流感病毒自1968年以来引发了最严重的疫情。我们对不同佐剂(明矾、AS03和Protollin)及给药途径(肌肉注射[i.m.]和鼻内[i.n.])进行了平行的临床前评估,以评估它们对灭活裂解疫苗(A/H3N2/纽约/55/2004)免疫原性和交叉反应性的影响。在加强免疫后2、6和19周,在BALB/c小鼠中测量了针对同源病毒和异源漂移株(A/H3N2/威斯康星/67/2005)的体液免疫和T细胞介导的免疫反应。与未加佐剂的疫苗相比,AS03和明矾佐剂的肌肉注射疫苗诱导的针对同型和异型毒株的功能性抗体滴度至少增加了8倍,且IgG2a水平低而IgG1水平高,表明是具有Th2趋势的Th1/Th2混合反应。Protollin佐剂的鼻内疫苗诱导的IgG1/IgG2a比值最低,这表明是具有Th1趋势的Th1/Th2混合型特征。这种佐剂疫苗是唯一能刺激黏膜IgA反应的疫苗。无论加强免疫后的时间如何,AS03佐剂的肌肉注射疫苗的血凝抑制(HAI)和微量中和(MN)滴度均高于Protollin佐剂的鼻内疫苗。最后,明矾佐剂的肌肉注射疫苗和低剂量Protollin佐剂的鼻内疫苗比未加佐剂的疫苗引发了显著更高的CD4(+) Th1和Th2反应以及更多产生γ干扰素(IFN-γ)的CD8(+) T细胞。我们的数据表明,本研究中测试的佐剂疫苗与未加佐剂的灭活流感疫苗相比,能引发针对A/H3N2毒株更强、更持久和更广泛的免疫反应。